Nilotinib exposure and dose intensity (400 mg twice daily)
| . | CML-CP (n = 95) . | CML-AP (n = 27) . |
|---|---|---|
| Median duration of nilotinib therapy, mo (range) | 24.7 (0-36) | 5.1 (0-38) |
| Median dose intensity,* mg/d (range) | 724 (151-800) | 769 (184-1149) |
| Patients with dose interruptions attributable to any AE, n (%) | 65 (68) | 13 (48) |
| Median duration of cumulative dose interruptions, d (range) | 24 (1-345) | 17 (4-234) |
| Median percentage time lost to dose interruptions while on nilotinib therapy, % (range) | 2.4 (0-60.1) | 1.1 (0-47.2) |
| . | CML-CP (n = 95) . | CML-AP (n = 27) . |
|---|---|---|
| Median duration of nilotinib therapy, mo (range) | 24.7 (0-36) | 5.1 (0-38) |
| Median dose intensity,* mg/d (range) | 724 (151-800) | 769 (184-1149) |
| Patients with dose interruptions attributable to any AE, n (%) | 65 (68) | 13 (48) |
| Median duration of cumulative dose interruptions, d (range) | 24 (1-345) | 17 (4-234) |
| Median percentage time lost to dose interruptions while on nilotinib therapy, % (range) | 2.4 (0-60.1) | 1.1 (0-47.2) |
AE indicates adverse event; AP, accelerated phase; CML, chronic myeloid leukemia; and CP, chronic phase.
Actual average dose intensity = cumulative dose given (ie, daily dose in mg/day)/duration of exposure (day).